In the midst of a global pandemic there has never been more focus on the companies that are developing the vaccines, and treatments to help people live longer, and healthier lives. Investors have already shown interest and commitment to investing in biotechnology with over $20 Billion of capital already allocated to biotechnology ETFs. Please join Defiance ETFs, and Nasdaq in discussing the most recent way to invest in biotechnology with the Defiance Nasdaq Junior Biotechnology ETF-ticker: IBBJ. IBBJ allows investors to gain targeted exposure to mid, and small-cap biotechnology equities and offers more of a “pure-play” way to access research and development spending in biotech.
What you will learn:
